A retrospective study demonstrated that GLP-1 receptor agonist use before pregnancy corresponded with lower risks for ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 receptor agonist therapy within one year.

Kwame Raoul is among several state AGs raising the alarm following complaints about online teleheath company Hims & Hers ...

Ozempic may also help people drink less alcohol. Primary care doctors are concerned about patients accessing GLP-1s through ...

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

GLP-1 and nutrition: managing risks for at-risk patients. Dr Almandoz shares key insights on malnutrition risks in post-bariatric and older patients, plus how to tailor care for better outcomes.

GLP-1s and nutrition: quality over restriction! Dr Almandoz shares how shifting from restrictive diets to evidence-based, ...

The quick answer is, it's complicated. Number one, quality. Number three, delay of the product. because it's no longer ...

“We would not be able to say for certain that a patient is reaping the full potential benefits of GLP-1 medications that have ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...